Hemostasis News and Research

RSS

Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.

Transradial cardiac catheterizations reduce complications, increase patient comfort

Each year, more than one million cardiac catheterizations are performed in the United States, and most of these procedures are performed through the groin to access the arteries that provide blood supply to the heart.

25 Aug 2011

ACS, 20 other organizations publish sixth edition of Physicians as Assistants at Surgery

In light of continuing Medicare and other third party-payer physician reimbursement issues and changes, the American College of Surgeons (ACS) and 20 other specialty surgical organizations have jointly published the sixth edition of Physicians as Assistants at Surgery, a guide that indicates whether an operation may call for the use of a physician as an assistant.

16 Aug 2011

ROTEM receives FDA clearance for new hemostasis analyzer

Surgical teams now can get faster and more complete information on the status of their patients' coagulation state from the ROTEM hemostasis analyzer, recently cleared by the Food and Drug Administration.

16 Aug 2011

Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. presented data from its clinical development program for OBI-1, an intravenous (IV) recombinant porcine factor VIII product (rpFVIII), intended for the treatment of bleeding in people with hemophilia A with inhibitors and in people with acquired hemophilia.

28 Jul 2011

LFB receives U.S. patent titled 'Monoclonal Antibodies with Enhanced ADCC Function'

LFB announced today that it has been recently issued U.S. Patent 7,931,895 titled "Monoclonal Antibodies with Enhanced ADCC Function" on April 26, 2011, by the U.S. Patent and Trademark Office.

8 Jul 2011

In vivo genome editing restores hemostasis in mouse model of blood clotting disorder

Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated the blood clotting disorder hemophilia in mice.

27 Jun 2011

FTC accepts Grifols and Talecris' Consent Agreement for public comment

Grifols, S.A. and Talecris Biotherapeutics Holdings Corp. announced today that the U.S. Federal Trade Commission has accepted for public comment a Consent Agreement that outlines the conditions necessary for Grifols' acquisition of Talecris to proceed.

1 Jun 2011

Transarterial embolization an effective alternative to endoscopy for acute peptic ulcer bleeding

Researchers from China report that in patients with peptic ulcer bleeding in whom endoscopy failed to control the bleeding, transarterial embolization is a safe procedure which reduces the need for surgery without increasing overall mortality and is associated with few complications.

24 May 2011

Cordis EXOSEAL Vascular Closure Device receives approval in the U.S.

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced the approval of the EXOSEAL Vascular Closure Device in the US. EXOSEAL incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure.

21 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Talecris, Grifols enter 'Consent Agreement' with FTC Staff

Grifols, S.A. and Talecris Biotherapeutics Holdings Corporation, announced today that they have signed a "Consent Agreement" with the Staff of the Bureau of Competition of the US Federal Trade Commission by means of which the conditions for the merger transaction between both companies are agreed.

2 May 2011

Jeffrey Modell Foundation opens new center for primary immunodeficiency

The Jeffrey Modell Foundation today announced the opening of a new center at Johns Hopkins Children's Center dedicated to the early diagnosis and appropriate treatment of children with primary immunodeficiency, a group of potentially fatal conditions in which the immune system malfunctions or is missing.

22 Apr 2011

DEKRA, Health Canada clear ORTHOCON's new Absorbable Bone Hemostat Matrix

ORTHOCON, Inc., a privately-held therapeutic device company, today announced that DEKRA and Health Canada have cleared its HEMASORB Absorbable Bone Hemostat Matrix for clinical use and sale in Europe and Canada.

22 Apr 2011

Baxter’s first quarter global sales increase 12% to $3.3 billion

Baxter International Inc. today announced strong financial results for the first quarter of 2011, and raised its outlook for full-year 2011.

From Baxter International Inc. 21 Apr 2011

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

Baxter International Inc. announced today the results of a phase III study evaluating the safety and efficacy of ARTISS in 75 patients.

From Baxter International Inc. 12 Apr 2011

CryoLife files PerClot IDE with FDA to initiate clinical trials in the U.S.

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has filed an IDE with the United States Food and Drug Administration to begin clinical trials for the purpose of obtaining Pre-Market Approval to distribute PerClot in the U.S. to control bleeding during surgical procedures or following traumatic injuries.

5 Apr 2011

Texas Children's Hospital and Baylor College of Medicine create Texas Children's Center for Global Health

Texas Children's Hospital and Baylor College of Medicine (BCM) today announced the creation of the Texas Children's Center for Global Health and the appointment of renowned physician-scientist Dr. Russell E. Ware as director.

31 Mar 2011

BioCer to showcase plant-based hemostasis and coated hernia repair technologies to China.

BioCer Entwicklungs GmbH, a Bayreuth, Germany based medical device manufacturer, has announced their attendance at the China Medical Equipment Fair (CMEF) Shenzhen, China 15th-19th April 2011. HaemoCer™ an Absorbable Polysaccharide Hemostat (APH) and Ti0²Mesh™ Hernia repair system will be on exhibit at the BioCer booth.

24 Mar 2011

Study finds reduction in pain favoring Mynx Vascular Closure Device to Angio-Seal Evolution Device

AccessClosure, Inc., the U.S. market segment leader in extravascular closure devices, announced today results from the first published study (Journal of NeuroInterventional Surgery) comparing the pain associated with deployment of different vascular closure devices (VCD) as the primary endpoint.

9 Mar 2011

Pending merger transaction between Grifols, Talecris has been extended

Grifols S.A. and Talecris Biotherapeutics Holdings Corp. today announced that the outside date under their merger agreement for closing their pending merger transaction has been extended to June 30, 2011 (from March 6, 2011).

5 Mar 2011